Form 4: Silence Therapeutics Director Richard Griffiths Boosts Stake with Significant ADS Purchases

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has reported the acquisition of 70,448 American Depositary Shares across two transactions in June 2025, increasing his direct beneficial ownership.

Summary

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc (SLN), reported changes in his beneficial ownership.
• On June 17, 2025, Mr. Griffiths acquired 31,399 American Depositary Shares (ADS) at a price of $5.29 per ADS.
• These 31,399 ADSs correspond to 94,197 Ordinary Shares, as each ADS is immediately convertible into three ordinary shares for no consideration.
• Following this transaction, his direct beneficial ownership was 11,392,779 American Depositary Shares.
• On June 18, 2025, Mr. Griffiths acquired an additional 39,049 American Depositary Shares at a price of $5.69 per ADS.
• These 39,049 ADSs correspond to 117,147 Ordinary Shares.
• After both transactions, his direct beneficial ownership increased to 11,431,828 American Depositary Shares.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director and 10% owner is generally viewed as a positive signal, indicating confidence in the company's valuation and future prospects.

Positives

• A Director and 10% owner, Richard Ian Griffiths, increased his stake in Silence Therapeutics plc by acquiring a total of 70,448 American Depositary Shares (ADS) across two transactions.
• Insider buying, especially by a significant owner and director, often signals confidence in the company's future prospects and valuation.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard insider trading disclosure for a biotechnology or pharmaceutical company, indicating a director's personal investment decision. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, acquired 70,448 American Depositary Shares (ADS) in two separate transactions on June 17 and June 18, 2025. These transactions are considered related party dealings due to Mr. Griffiths's position within the company.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of management confidence in the company's future performance and value.

Key Dates

Keywords

Silence Therapeutics plc, SLN, Richard Ian Griffiths, Director, 10% Owner, American Depositary Shares, ADS, Ordinary Shares, Insider Trading, Beneficial Ownership, SEC Form 4, Stock Purchase, Rule 10b5-1